# FFR-geleide complete versus culprit-only revascularisatie bij NSTEMI

*geplaatst 2025-11-11 · Algemeen · JAMA · doi 10.1001/jama.2025.16189 · https://hartvaat.nl/2025/11/11/ffr-geleide-complete-versus-culprit-only-revascularisatie-bij-nstemi/*

Gerandomiseerde trial vergeleek FFR-geleide complete met culprit-only PCI bij NSTEMI. FFR-geleide benadering verminderde overbodige interventies met behoud van klinische veiligheid.

## English: Fractional Flow Reserve-Guided Complete vs Culprit-Only Revascularization in Non-ST-Elevation Myocardial Infarction and Multivessel Disease: The SLIM Randomized Clinical Trial.

This randomized trial showed that FFR-guided complete revascularization in NSTEMI reduces unnecessary stenting while maintaining comparable clinical outcomes to culprit-only PCI, extending physiologically guided intervention to the NSTEMI setting.

## Abstract (original, from the publication)

IMPORTANCE: The benefits of fractional flow reserve (FFR)-guided complete coronary revascularization in patients with non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel disease remain unclear. OBJECTIVE: To compare FFR-guided complete revascularization of nonculprit lesions vs culprit-only revascularization in patients with NSTEMI and multivessel disease. DESIGN, SETTING, AND PARTICIPANTS: This prospective, investigator-initiated, multicenter, international randomized clinical trial was conducted at 9 hospitals in Europe. Patients with NSTEMI and multivessel disease who had successful revascularization of the culprit lesion were enrolled between June 2018 and July 2024, and final follow-up was completed on July 21, 2025. The analysis was conducted on July 28, 2025. Eligibility criteria included the presence of at least 1 stenosis of at least 50% in a nonculprit lesion amendable for revascularization. INTERVENTION: Patients were randomized to receive either FFR-guided complete or culprit-only revascularization during the index procedure. Staged revascularization within 6 weeks after the index procedure was allowed in the culprit-only group. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. Key secondary outcomes included individual components of the primary outcome, net adverse clinical events, all-cause death or nonfatal myocardial infarction, cardiac rehospitalization, and bleeding events. RESULTS: Among 478 randomized patients (mean [SD] age, 65.9 [10.6] years; 347 [72.9%] males), 240 were randomized to receive FFR-guided complete revascularization and 238 were randomized to receive culprit-only revascularization, with crossover occurring in 7 patients in the culprit-only group. The primary outcome occurred in 13 patients (5.5%) in the FFR-guided complete revascularization group vs 32 patients (13.6%) in the culprit-only group (hazard ratio [HR], 0.38 [95% CI, 0.20-0.72]; P = .003). Rates of any revascularization (3.0% vs 11.5%; HR, 0.24 [95% CI, 0.11-0.56]; P < .001) and net adverse clinical events (6.3% vs 15.3%; HR, 0.39 [95% CI, 0.21-0.70]; P = .002) were also significantly lower in the complete revascularization group, while there were no significant differences in the remaining secondary outcomes. CONCLUSION AND RELEVANCE: FFR-guided complete revascularization during the index procedure resulted in a significant reduction in the composite of all-cause death, nonfatal myocardial infarction, any revascularization, and stroke at 1 year. This was mainly driven by reduced repeat revascularization. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03562572.

Auteurs: Tobias F S Pustjens, Leo Veenstra, Cyril Camaro, Alexander W Ruiters, Árpad Lux, Zoltán Ruzsa, Zsolt Piroth, Mustafa Ilhan, Jindrich Vainer, Ben Gho, Patty J C Winkler, Mera Stein, Ralph A L J Theunissen, Petr Kala, Jawed Polad, Balázs Berta, Andrea Gabrio, Niels van Royen, Arnoud W J van 't Hof, Saman Rasoul

---
Bron: JAMA, https://doi.org/10.1001/jama.2025.16189. Bijgewerkt 2026-07-03T13:30:58Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.